Information Provided By: 
Fly News Breaks for March 29, 2018
FATE
Mar 29, 2018 | 09:28 EDT
Piper Jaffray analyst Edward Tenthoff said he was "highly encouraged" by the preliminary safety and efficacy data from a Phase I trial on Fate Therapeutics' NK100 in two ovarian cancer patients that was presented at a medical summit. The first patient progressed and the second had stable disease at 28 days with early signs of tumor regression, he noted. Tenthoff said Fate remains a 2018 top pick and reiterated his Overweight rating and $20 price target on the shares.
News For FATE From the Last 2 Days
There are no results for your query FATE
